MedTrace Logo

Leuvectin Followed By Surgery in Treating Patients With Stage II or Stage III Prostate Cancer

NCT00004050 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 13

Last updated 2014-07-29

No results posted yet for this study

Summary

RATIONALE: Inserting the gene for interleukin-2 into a person's cancer cells may improve the body's ability to fight cancer. Using Leuvectin to deliver this gene may be an effective treatment for prostate cancer.

PURPOSE: Phase II trial to study the effectiveness of Leuvectin followed by surgery in treating patients who have stage II or stage III prostate cancer.

Conditions

Interventions

BIOLOGICAL

Leuvectin

Leuvectin injected intratumorally followed by prostatectomy

Sponsors & Collaborators

  • Jonsson Comprehensive Cancer Center

    collaborator OTHER

  • National Cancer Institute (NCI)

    collaborator NIH

  • Vical

    lead INDUSTRY

Principal Investigators

  • Arie Belldegrun, MD, FACS · Jonsson Comprehensive Cancer Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
1999-06-30
Primary Completion
2003-04-30
Completion
2003-04-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00004050 on ClinicalTrials.gov